Lesson
Close the Ribosomal Pocket Around the Mutilin Core
Lefamulin is a semisynthetic systemic pleuromutilin. Its mutilin core binds through an induced fit at the A and P sites of the peptidyl transferase center in domain V of 23S rRNA, preventing correct tRNA positioning and bacterial protein synthesis.
- Mutilin core
- Peptidyl transferase center
- 23S rRNA
- Induced fit
- tRNA positioning
The scaffold reaches A and P sites in 23S rRNA.
Hydrogen, hydrophobic, and van der Waals forces align the core.
An induced fit locks the drug into the target.
Correct tRNA positioning and protein synthesis fail.
The scaffold defines a distinct class
Lefamulin is not a macrolide, lincosamide, or oxazolidinone even though these agents also affect the 50S ribosome. The pleuromutilin scaffold creates a different binding geometry.
The target spans A and P sites
Hydrogen bonds, hydrophobic contacts, and van der Waals forces close the ribosomal pocket around the mutilin core within the peptidyl transferase center.
Translation fails at tRNA positioning
Induced fit prevents correct tRNA placement and peptide transfer. Lefamulin does not inhibit DNA gyrase or bacterial cell-wall synthesis.
Static or cidal depends on the organism
In vitro activity is bactericidal against selected S. pneumoniae, H. influenzae, and M. pneumoniae isolates and bacteriostatic against selected S. aureus and S. pyogenes isolates.
Quick check
Lesson
Name the CABP Coverage and Preserve Its Missing Organisms
The adult CABP label includes susceptible pneumococcus, MSSA, H. influenzae, Legionella, Mycoplasma, and Chlamydophila. Lefamulin is not active against Enterobacterales or Pseudomonas, and in vitro MRSA activity is not equivalent to proven MRSA pneumonia efficacy.
- Pneumococcus
- MSSA
- H. influenzae
- Atypical bacteria
- Major gaps
Susceptible pneumococcus, MSSA, and H. influenzae fit.
Legionella, Mycoplasma, and Chlamydophila are labeled.
Choose another pathway when these organisms matter.
ABC-F, Cfr, and L3 or L4 changes can reduce activity.
The label combines typical and atypical CABP activity
Lefamulin covers labeled susceptible pneumococcus, MSSA, H. influenzae, Legionella, Mycoplasma, and Chlamydophila within adult CABP.
Two gram-negative groups remain outside
Enterobacterales and Pseudomonas aeruginosa are not covered. Prior Pseudomonas isolation or advanced structural lung disease requires another pathway.
MRSA creates an evidence boundary
MRSA isolates can show in vitro susceptibility, but adequate controlled trials have not established clinical efficacy for MRSA CABP. Use proven MRSA therapy when coverage is required.
Resistance targets the protected pocket
ABC-F proteins, Cfr methylation, and L3 or L4 changes can reduce activity. Macrolide resistance alone does not prove lefamulin resistance.
Quick check
Lesson
Place Lefamulin Inside Adult Pneumonia Care
Lefamulin is approved for adult community-acquired bacterial pneumonia. The IDSA clinical pathway positions it as an option for selected nonsevere hospitalized CAP patients who cannot use beta-lactams, macrolides, or fluoroquinolones.
- Adult CABP
- Bacterial probability
- Nonsevere alternative
- Severe CAP boundary
- Daily reassessment
Separate bacterial pneumonia from viral or noninfectious disease.
Severe CAP requires a broader evidence-based pathway.
Document why standard CAP options are unsuitable.
Use diagnostics, response, and complications to refine therapy.
Begin with bacterial pneumonia, not a drug
Confirm a compatible adult syndrome using history, examination, imaging, oxygenation, viral diagnostics, and bacterial probability. Lefamulin does not treat viral bronchitis.
Alternative status requires a reason
Current pathway language allows lefamulin in nonsevere CAP when beta-lactams, macrolides, or fluoroquinolones are unsuitable. Document the allergy, intolerance, interaction, or other constraint.
Severe CAP needs a broader pathway
Shock, mechanical ventilation, MRSA risk, Pseudomonas risk, or other severe features require evidence-based combination strategies rather than lefamulin monotherapy.
Daily review can stop unnecessary treatment
Reassess stability, viral results, cultures, complications, mimics, adverse effects, and de-escalation. A persistent opacity is not automatically antibiotic failure.
Quick check
Lesson
Let Route and Hepatic Function Set the Regimen
Adults receive 600 mg orally every 12 hours for five days or 150 mg IV every 12 hours over 60 minutes for five to seven days. IV therapy can transition to oral therapy, but hepatic restrictions differ by route.
- 600 mg oral
- 150 mg IV
- Route transition
- Child-Pugh class
- Renal function
Use five days with fasting administration.
Infuse over 60 minutes for five to seven days.
Extend IV dosing to every 24 hours.
The tablet has not been studied and is not recommended.
Oral treatment is a five-day course
The labeled oral regimen is 600 mg every 12 hours for five days. That is 1200 mg per day, not a single daily 600 mg dose.
Intravenous treatment uses a longer range
The labeled IV regimen is 150 mg every 12 hours infused over 60 minutes for five to seven days, with an option to complete therapy orally.
Hepatic impairment splits the route
For Child-Pugh C disease, IV dosing becomes 150 mg every 24 hours. Oral tablets are not recommended in Child-Pugh B or C disease.
Renal impairment does not change the dose
No adjustment is required even with hemodialysis, but dialysis-associated electrolyte and QT risks still require assessment. Lefamulin is not dialyzable.
Quick check
Lesson
Build the Dose Around Fasting, Water, and Time
Oral lefamulin must be taken at least one hour before a meal or two hours after a meal, swallowed whole with 6 to 8 ounces of water, and never crushed or divided. Missed doses follow an eight-hour rule.
- Fasting window
- Whole tablet
- 6 to 8 ounces
- Eight-hour rule
- Adherence
Or wait two hours after a meal.
Use 6 to 8 ounces and never crush or divide.
Take a missed dose only when this window remains.
Meals, work, sleep, cost, and interactions must fit.
Food timing protects exposure
Take each dose at least one hour before a meal or two hours afterward. Do not copy with-food counseling from another antibiotic.
The tablet remains whole
Swallow the blue 600 mg tablet whole with 6 to 8 ounces of water. A patient who cannot swallow it should use another feasible plan rather than crush it.
Eight hours determines a missed dose
Take a missed dose when at least eight hours remain before the next scheduled dose. If fewer than eight hours remain, skip it and resume the schedule.
A short course can still be operationally difficult
Twice-daily fasting windows, whole-tablet swallowing, interactions, cost, and access can defeat adherence. Test the schedule with the patient before discharge.
Quick check
Lesson
Turn One Vial and One Buffered Bag Into a Safe Infusion
The entire 150 mg in 15 mL vial is diluted into the supplied 250 mL citrate-buffered normal saline bag, mixed, inspected, and infused over 60 minutes without other additives or series connections.
- 150 mg vial
- 250 mL buffered bag
- Aseptic technique
- 60-minute infusion
- Storage limits
Add the entire vial aseptically.
Use the supplied bag and add no other product.
Reject particles, discoloration, or container damage.
Deliver the prepared dose over 60 minutes.
The supplied diluent is part of preparation
Add the entire 15 mL vial to the supplied 250 mL citrate-buffered 0.9 percent sodium chloride bag. Do not infuse the vial undiluted.
Compatibility is intentionally narrow
Do not add other products to the bag and do not use it in series connections. Inspect for particles, discoloration, and container damage.
The pump rate follows one hour
Infuse 250 mL over 60 minutes, which is 250 mL per hour. A faster rate can increase concentration-related QT effects.
Storage depends on temperature
After dilution, the bag may be stored for up to 24 hours at room temperature or 48 hours refrigerated at 2 to 8 degrees Celsius.
Quick check
Lesson
Make Repolarization Risk a Selection Decision
Lefamulin can prolong QT, and risk rises with exposure, infusion rate, baseline QT disease, ventricular arrhythmia, electrolyte disturbance, organ failure, and other QT-prolonging drugs.
- Baseline QTc
- Torsades history
- Electrolytes
- QT drugs
- Exposure
Avoid known long QT and ventricular arrhythmias.
Remove modifiable torsades risks before therapy.
Avoid additive antiarrhythmics, antipsychotics, and antibiotics.
Preserve dosing, hepatic rules, and the 60-minute infusion.
Some patients should receive another drug
Avoid lefamulin with known QT prolongation, ventricular arrhythmias including torsades, or Class IA or III antiarrhythmics when an alternative is available.
The medication list is only one layer
Hypokalemia, hypomagnesemia, bradycardia, dialysis, liver disease, and acute illness can amplify repolarization risk. Correct modifiable factors.
Other QT drugs create additive uncertainty
Avoid antipsychotics, erythromycin, moxifloxacin, tricyclic antidepressants, and other QT-prolonging combinations when possible.
Concentration and rate matter
Higher exposure or a faster IV infusion can increase QT prolongation. Preserve hepatic restrictions, interaction screening, exact dose, interval, and 60-minute infusion.
Quick check
Lesson
Separate Oral First-Pass Effects From Intravenous Exposure
CYP3A and P-gp inducers reduce lefamulin exposure. Strong inhibitors markedly raise oral exposure. Oral lefamulin also increases sensitive CYP3A substrates, while IV lefamulin does not show the same perpetrator effect.
- CYP3A inducers
- P-gp
- Oral inhibitors
- Sensitive substrates
- Route distinction
Reduced exposure can create treatment failure.
Markedly increased lefamulin exposure raises adverse-effect risk.
Oral lefamulin can increase CYP3A substrate concentrations.
Pimozide and similar drugs can provoke torsades.
Inducers can create treatment failure
Avoid strong or moderate CYP3A and P-gp inducers with either route unless benefit outweighs risk. Rifampin has a much larger effect on oral exposure.
Strong inhibitors threaten oral safety
Avoid strong CYP3A or P-gp inhibitors with oral lefamulin and monitor adverse effects with moderate inhibitors. The IV interaction magnitude differs.
Oral lefamulin can raise other drugs
Monitor sensitive CYP3A substrates such as alprazolam, diltiazem, verapamil, simvastatin, or vardenafil. Oral lefamulin can substantially increase exposure.
A QT-prolonging sensitive substrate is contraindicated
Oral lefamulin with pimozide or another sensitive CYP3A substrate that prolongs QT can provoke torsades. This is not a monitor-only combination.
Quick check
Lesson
Replace a Warning List With Actionable Ownership
Embryo-fetal harm, lactation exposure, gastrointestinal effects, infusion-site reactions, liver-enzyme elevation, CDAD, cytopenias, and cardiac symptoms require route-specific counseling and action thresholds.
- Pregnancy testing
- Contraception
- Lactation
- Hepatic enzymes
- CDAD
Animal evidence supports potential fetal harm.
Extend protection beyond the final dose.
Pump and discard during therapy and for two days after.
Screen severity rather than calling every symptom expected.
Pregnancy risk uses a current narrative
Animal findings support potential fetal harm, and human pregnancy data are unavailable. Verify pregnancy status and use a better-supported alternative when possible rather than assigning a retired letter.
Two days follows the final dose
Use effective contraception during treatment and for two days afterward. Pump and discard human milk during treatment and for two days after the final dose.
Common effects differ by route
Oral trials most often reported diarrhea, nausea, and vomiting. IV therapy added administration-site reactions, while either route can elevate liver enzymes.
Diarrhea still requires a severity screen
Distinguish expected mild diarrhea from C. difficile-associated disease using frequency, blood, fever, pain, dehydration, timing, and recent antibiotic exposure.
Quick check
Lesson
Close the CABP Loop Before the First Dose
Lefamulin is complete only when adult bacterial pneumonia, severity, resistant-pathogen risk, reason for alternative selection, exact route and regimen, administration, QT and CYP safety, organ function, reproductive counseling, response, transition, and exit agree.
- Diagnosis
- Evidence position
- Exact product
- Safety ownership
- Exit criteria
Find bleeding, suppression, hemolysis, depletion, and absorption effects
Use teach back for products, schedules, interactions, and danger signs
Time CBC and cause-specific studies to the expected response
Act on unexplained anemia, abnormal smear, pancytopenia, hemolysis, or failure
Preserve antibodies, effective analgesia, complications, and preferences
Establish adult care before pediatric care closes
Audit delays and solve barriers without blame
Assign every laboratory, vaccine, referral, and response review
Confirm bacterial disease and resistant-pathogen risks.
State why standard options do not fit.
Preserve dose, food, infusion, hepatic, QT, and CYP rules.
Use stability, diagnostics, toxicity, and duration.
State why lefamulin belongs
Name the adult CABP syndrome and why standard beta-lactam, macrolide, or fluoroquinolone options are unsuitable. Do not let novelty become the indication.
Preserve resistant-pathogen boundaries
Use another pathway for severe disease, MRSA, Pseudomonas, Enterobacterales, empyema, abscess, or another complication that exceeds lefamulin monotherapy.
Make execution reconstructable
Write route, dose, interval, duration, food or infusion technique, hepatic rule, interaction decisions, ECG and electrolyte plan, and reproductive counseling.
Define response and exit
Use temperature, heart rate, respiratory rate, oxygenation, blood pressure, mental status, diagnostic results, oral tolerance, adverse effects, and completion criteria.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 164 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.